Beta-adrenergic receptor blockade and pediatric dilated cardiomyopathy

Progress in Pediatric Cardiology

Volumn 24, Issue 1, 2007, Pages 51-57

  Kaufman, Beth D ^a   Shaddy, Robert E ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

adrenergic receptor blocker; Clinical trials; Dilated cardiomyopathy; Review

Indexed keywords

ADRENERGIC RECEPTOR; BISOPROLOL; CARVEDILOL; DIGOXIN; DIURETIC AGENT; METOPROLOL;

BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DRUG MECHANISM; DRUG POTENTIATION; DRUG WITHDRAWAL; HEART FAILURE; HEART VENTRICLE FUNCTION; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 35348815480     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2007.08.004     Document Type: Review

References (50)

1. Petrofski J.A., and Koch W.J. The [beta]-adrenergic receptor kinase in heart failure. J Mol Cell Cardiol 35 10 (2003) 1167-1174
2. Port J.D., and Bristow M.R. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol 33 5 (2001) 887-905
3. Cohn J.N., Ferrari R., and Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35 3 (2000) 569-582
4. Colucci W.S., et al. Adrenergic overload and apoptosis in heart failure: implications for therapy. J Card Fail 6 2 Suppl 1 (2000) 1-7
5. Bristow M.R. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 80 11A (1997) 26L-40L
6. Buchhorn R., et al. Beta-receptor downregulation in congenital heart disease: a risk factor for complications after surgical repair?. Ann Thorac Surg 73 2 (2002) 610-613
7. Buchhorn R., et al. Effects of therapeutic beta blockade on myocardial function and cardiac remodelling in congenital cardiac disease. Cardiol Young 13 1 (2003) 36-43
8. Kozlik-Feldmann R., et al. Distribution of myocardial beta-adrenoceptor subtypes and coupling to the adenylate cyclase in children with congenital heart disease and implications for treatment. J Clin Pharmacol 33 7 (1993) 588-595
9. Waagstein F., et al. Beta-blockers in dilated cardiomyopathies: they work. Eur Heart J 4 Suppl A (1983) 173-178
10. Eichhorn E.J., et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 82 2 (1990) 473-483
11. Olsen S.L., et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 25 6 (1995) 1225-1231
12. Waagstein F., et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 342 8885 (1993) 1441-1446
13. Gilbert E.M., et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 88 3 (1990) 223-229
14. Shaddy R.E., et al. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. J Heart Lung Transplant 18 3 (1999) 269-274
15. Bristow M.R., et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 94 11 (1996) 2807-2816
16. Packer M., et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective randomized evaluation of carvedilol on symptoms and exercise [see comments]. Circulation 94 11 (1996) 2793-2799
17. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 9169 (1999) 2001-2007
18. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 9146 (1999) 9-13
19. Packer M., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106 17 (2002) 2194-2199
20. Sanderson J.E., et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 34 5 (1999) 1522-1528
21. Metra M., et al. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 102 5 (2000) 546-551
22. Packer M., et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 141 6 (2001) 899-907
23. Poole-Wilson P.A., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 9377 (2003) 7-13
24. Ghali J.K., et al. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 105 13 (2002) 1585-1591
25. Deedwania P.C., et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 149 1 (2005) 159-167
26. Flather M.D., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 3 (2005) 215-225
27. Sliwa K., et al. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. J Am Coll Cardiol 44 9 (2004) 1825-1830
28. Hunt S.A., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 6 (2005) 1116-1143
29. Laer S., et al. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 143 5 (2002) 916-922
30. Buchhorn R., et al. Beta-blocker therapy of severe congestive heart failure in infants with left to right shunts. Am J Cardiol 81 11 (1998) 1366-1368
31. Buchhorn R., et al. Propranolol treatment of congestive heart failure in infants with congenital heart disease: The CHF-PRO-INFANT Trial. Congestive heart failure in infants treated with propanol. Int J Cardiol 79 2-3 (2001) 167-173
32. Shaddy R.E. Beta-blocker therapy in young children with congestive heart failure under consideration for heart transplantation. Am Heart J 136 1 (1998) 19-21
33. Shaddy R.E., et al. Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J 129 1 (1995) 197-199
34. Lewis A.B. Late recovery of ventricular function in children with idiopathic dilated cardiomyopathy. Am Heart J 138 2 Pt 1 (1999) 334-338
35. Bruns L.A., et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 138 4 (2001) 505-511
36. Rusconi P., et al. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J Heart Lung Transplant 23 7 (2004) 832-838
37. Gachara N., et al. Efficacy and safety of carvedilol in infants with dilated cardiomyopathy: a preliminary report. Indian Heart J 53 1 (2001) 74-78
38. Azeka E., et al. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. J Am Coll Cardiol 40 11 (2002) 2034-2038
39. Blume E.D., et al. Prospective single-arm protocol of carvedilol in children with ventricular dysfunction. Pediatr Cardiol 27 3 (2006) 336-342
40. Williams R.V., Tani L.Y., and Shaddy R.E. Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction. J Heart Lung Transplant 21 8 (2002) 906-909
41. Greenway S.C., and Benson L.N. The use of carvedilol in pediatric heart failure. Cardiovasc Hematol Disord Drug Targets 6 1 (2006) 35-42
42. Shaddy R.E., et al. The pediatric randomized carvedilol trial in children with heart failure: rationale and design. Am Heart J 144 3 (2002) 383-389
43. Wagoner L.E., Starling R.C., and O'Connor C.M. Cardiac function and heart failure. J Am Coll Cardiol 47 11 Suppl (2006) D18-D22
44. Rosenthal D., et al. International Society for Heart and Lung Transplantation: practice guidelines for management of heart failure in children. J Heart Lung Transplant 23 12 (2004) 1313-1333
45. Josephson C.B., et al. A case series of systemic right ventricular dysfunction post atrial switch for simple d-transposition of the great arteries: the impact of beta-blockade. Can J Cardiol 22 9 (2006) 769-772
46. Giardini A., et al. A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in patients with systemic right ventricle. Int J Cardiol (2006)
47. Doughan A.R., McConnell M.E., and Book W.M. Effect of beta blockers (carvedilol or metoprolol XL) in patients with transposition of great arteries and dysfunction of the systemic right ventricle. Am J Cardiol 99 5 (2007) 704-706
48. Ratnapalan S., et al. Digoxin-carvedilol interactions in children. J Pediatr 142 5 (2003) 572-574
49. Liggett S.B., et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 103 30 (2006) 11288-11293
50. Wagoner L.E., et al. Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure. Am Heart J 144 5 (2002) 840-846